Statement on the Death of Health Decisions' CEO Michael Rosenberg, MD, MPH

Durham, North Carolina--Health Decisions confirms with deep regret and great sadness that founder and CEO Michael Rosenberg, MD, MPH, died at approximately 11:00 a.m. December 8, 2014 in a private plane crash near Montgomery County Airpark in Gaithersburg, MD, a Washington DC suburb.

"Everyone at Health Decisions is devastated by the loss of our friend and colleague Michael Rosenberg," stated Health Decisions Vice President, Clinical Affairs Patrick Phillips, D Phil. "The thoughts of the management and employees of Health Decisions go out to Dr. Rosenberg's family as well as to the families of the other passengers."

"We can best honor Michael by carrying on and realizing his vision of a more efficient approach to clinical development," Dr. Phillips stated. "We are committed to that goal."

Dr. Phillips stated that the Health Decisions Executive Team would announce succession plans at an appropriate time. No changes are anticipated in the company's day-to-day business activities.

Dr. Rosenberg founded Health Decisions, a leading Clinical Research Organization, in 1989 with the conviction that the development of new medicines and medical devices could and should be more efficient. Dr. Rosenberg's focus on improving the efficiency of clinical development never wavered. The Association of Clinical Research Professionals recognized Dr. Rosenberg's contributions with the 2014 Innovation in Clinical Research Award. Also in 2014, The Triangle Business Journal honored Dr. Rosenberg with its Life Sciences CEO of the Year Award. In addition to serving as Health Decisions' CEO, Dr. Rosenberg was an award-winning author. His book, The Agile Approach to Adaptive Research: Optimizing Efficiency in Clinical Research (Wiley 2010) received the Journal for Clinical Studies JCS Library Award and was selected for the First Clinical Research Bookshelf by The Journal of Clinical Research Best Practices.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.